
BioPlus participated in the global medical aesthetics conference ‘Aesthetic NEXT 7.0,’ held in Dallas, Texas from September 4 to 7 (local time). (Source: BioPlus)
At the event, BioPlus introduced its latest product lineup, featuring the topical cell booster ‘Shine+Aura’ and its new ingredient brand ‘HUGRO.’ Shine+Aura attracted strong attention for its demonstrated efficacy at the cellular level, distinguishing it from conventional skin boosters. The product incorporates two proprietary technologies: △AUT (Anti-Ubiquitination Technology), which prevents protein degradation, and △BMTS (Bio-Material Transdermal System), which enhances skin absorption.
The newly introduced ingredient brand HUGRO also received considerable interest from international buyers and practitioners. Developed with proprietary technology that enhances the performance of human-derived growth factors such as EGF and TGF, HUGRO serves as a versatile platform for both skin rejuvenation and hair restoration solutions. BioPlus plans to roll out a series of products leveraging this technology.
Throughout the event, BioPlus engaged in active discussions with global buyers and strategic partners to explore collaborative opportunities and future business prospects.
Jung Jae-won, President of BioPlus USA, commented, “The positive response we received at Aesthetic NEXT validates the strong global potential of our proprietary technologies. Leveraging our innovative ingredients and patented delivery systems, we will continue to strengthen our presence in the international market.”
Meanwhile, BioPlus is a South Korea-based biotechnology company specializing in medical aesthetics. The company develops and manufactures a broad portfolio of products, including hyaluronic acid dermal fillers, advanced skincare solutions, and innovative bio-materials, all powered by proprietary technology. BioPlus is committed to accelerating its growth in the global market through continuous R&D and international partnerships.